OTC:APHD
VERDE BIO HOLDINGS, INC.
A financially distressed holding company undergoing major capital infusion to reverse negative cash flows and fund future growth initiatives.
Key Metrics
Investment Thesis
Bull Case
Investors might consider APHD as a high-risk turnaround play where the $16.7M equity base provides a strong foundation for future asset acquisition or product launch. The absence of long-term debt and the presence of tangible fixed assets suggest management is preparing to pivot from fundraising to operational deployment.
Bear Case
The stock presents extreme risk due to zero revenue, negative cash flow from operations, and a depleted cash balance that threatens immediate insolvency. With current liabilities exceeding current assets and a massive operating loss, the company lacks the fundamentals required for sustainable growth without further dilutive financing events.
About VERDE BIO HOLDINGS, INC.
VERDE BIO HOLDINGS, INC. (APHD) is an emerging biotechnology or agricultural holding entity operating in the OTC market with significant capital restructuring activity. The company has recently engaged in substantial financing to address severe operational losses and liquidity constraints, positioning itself for future asset acquisition or product development cycles.
Analysis
Management Discussion
The company's financial performance reflects a deep restructuring phase characterized by a massive cash burn of $872k from operations against a net loss of $1.8M. Management has successfully mobilized significant capital, evidenced by $608k in financing cash flows and a large paid-in capital balance, but the severe decline in cash reserves from $141k to $26k highlights critical liquidity pressure.
Industry Overview
The OTC biotechnology or agricultural holding sector often features early-stage companies with limited revenue that rely on equity financing to fund R&D or asset acquisition before achieving commercial viability. Companies in this space face high volatility and liquidity challenges as they navigate the gap between capital raising and product monetization.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 |
|---|---|
| Revenue | $0 |
| Cost of Revenue | $-926.1K |
| Gross Profit | $926.1K |
| Operating Expenses | $2.6M |
| Operating Income | $-1.6M |
| Depreciation | $61.6K |
| Non-Operating Income | $-134.3K |
| Interest Expense | $65.9K |
| Pre-Tax Income | $-1.8M |
| Income Tax | $0 |
| Continuing Ops | $-1.8M |
| Discontinued Ops | $0 |
| Net Income | $-1.8M |
| Minority Interest | $0 |
| Net to Common | $-1.8M |
| Metric | 2023 |
|---|---|
| Current Assets | $97.7K |
| Prepaid Expenses | $0 |
| Other Current Assets | $97.7K |
| Long-Term Assets | $4.1M |
| PP&E (Net) | $2.7M |
| Operating Leases | $19.9K |
| Other LT Assets | $1.3M |
| Total Assets | $4.2M |
| Current Liabilities | $1.8M |
| Current Leases | $21.3K |
| Other Current Liab | $1.8M |
| Long-Term Liabilities | $0 |
| LT Operating Leases | $0 |
| Other LT Liab | $0 |
| Total Liabilities | $1.8M |
| Shareholders' Equity | $2.2M |
| Paid-In Capital | $16.7M |
| Retained Earnings | $-16.0M |
| Total L&E | $4.2M |
| Metric | 2023 |
|---|---|
| Net Income (CFO) | $-1.8M |
| Non-Cash Adjustments | $866.0K |
| Working Capital Changes | $36.0K |
| Cash from Operations | $-872.2K |
| Capital Expenditures | $7.0K |
| Cash from Investing | $148.0K |
| Cash from Financing | $608.8K |
| FX Effect | $0 |
| Net Change in Cash | $-115.4K |
| Beginning Cash | $141.2K |
| Ending Cash | $25.8K |
Frequently Asked Questions
How does VERDE BIO HOLDINGS, INC. make money?
1) Capital Markets & Financing: The primary activity involves raising equity through paid-in capital of $16.7M to resolve a $16.0M retained earnings deficit. 2) Asset Management: The firm manages a balance sheet with $4.2M in total assets, including $2.7M in net fixed assets and $1.3M in other long-term assets. 3) Operational Services: Limited current revenue generation suggests the business is currently in a build-up or turnaround phase rather than active commercial sales.
What are the main risks for APHD?
1) Severe Liquidity Crisis: Net change in cash is negative $115k with ending cash at only $26k, creating immediate solvency risk. 2) Negative Operating Performance: Cash flow from operations of -$872k and a net profit loss of $1.8M indicate an inability to generate organic value. 3) Revenue Instability: Total revenue is reported as zero, exposing the company to high volatility if future commercialization fails. 4) High Financing Dependence: Survival relies entirely on continued financing inflows rather than operational cash generation.
What is APHD's competitive advantage?
1) Substantial Equity Buffer: With $16.7M in paid-in capital, the company has secured significant shareholder support to weather operational losses. 2) Clean Liability Structure: The company holds zero long-term liabilities, offering flexibility for future debt financing or acquisitions. 3) Asset Base Preservation: Despite cash outflows, the firm maintains tangible net fixed assets of $2.7M as collateral for potential future operations.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.